Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CRIS, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| chondrocyte-alginate gel suspension | Vesicoureteral Reflux | Phase 3 · NCT00004487 | Unknown |
| Emavusertib (CA-4948) | Myelodysplastic Syndromes | Phase 2 · NCT05178342 | Terminated |
| Zanubrutinib | Chronic Lymphocytic Leukemia | Phase 2 · NCT07271667 | Recruiting |
| Fimepinostat (CUDC-907) | Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including… | Phase 2 · NCT02674750 | Completed |
| Smac Mimetic GDC-0917 | Lymphoma | Phase 1 · NCT01908413 | Terminated |
| HDAC/EGFR/HER2 Inhibitor CUDC-101 | Head and Neck Cancer | Phase 1 · NCT01384799 | Completed |
| mFOLFOX7 | Gastric Cancer | Phase 1 · NCT05187182 | Recruiting |
| Onvatilimab (CI-8993) | Solid Tumor | Phase 1 · NCT04475523 | Completed |
| Cenopodlin (CA-170) | Advanced Solid Tumors or Lymphomas | Phase 1 · NCT02812875 | Completed |
Also used in these trials (approved or third-party drugs, not CRIS's own candidates): Venetoclax, Ibrutinib, Durvalumab, Gemcitabine Hydrochloride, Cisplatin, Nivolumab, Pembrolizumab, Rituximab, Trastuzumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CRIS holds $5.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $9.3M/quarter from operations, an estimated runway of 1.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 70 · High
2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has concluded there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date…10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CRIS files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Stonepine Capital Management, LLC | Institution (13G, 5%+) | 4,025,992 | 42.32% | 2026-03-17 |
| Thomas A. Satterfield, Jr. | 5%+ holder (13G) | 616,565 | 6.48% | 2026-09-30 |
| Armistice Capital, LLC | Institution (13G, 5%+) | 372,000 | 3.91% | 2026-09-30 |
| Nantahala Capital Management, LLC | Institution (13G, 5%+) | 258,739 | 2.72% | 2026-09-30 |
| James E Dentzer President & CEO, Director · +970,089 options |
Insider | 148,730 | 1.56% | 2026-03-20 |
| Diantha Duvall CFO · +422,283 options |
Insider | 77,707 | 0.82% | 2026-03-20 |
| Jonathan B. Zung CDO · +423,986 options |
Insider | 66,667 | 0.70% | 2026-03-20 |
| Ahmed MD Hamdy CMO · +400,001 options |
Insider | 66,667 | 0.70% | 2026-03-20 |
| Marc Rubin Director · +101,201 options |
Insider | 28,108 | 0.30% | 2026-03-20 |
| Kenneth I Kaitin Director · +21,200 options |
Insider | 11,407 | 0.12% | 2026-03-31 |
Share count 9,512,232 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CRIS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →